ACIU
AC Immune SA
NASDAQ · Healthcare · Biotechnology · CH
$2.20
+5.26%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.22
- Revenue estimate
- $328.7K
Latest reported
- Last report date
- Nov 4, 2026
- EPS actual
- -$0.16
- EPS estimate
- -$0.22
- Revenue actual
- —
- Revenue estimate
- $328.7K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 10
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +43.9%
- Revenue beats (12Q)
- 6
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 4, 2026 | -$0.22 | -$0.16 | Beat 27.27% | — |
| Aug 5, 2026 | -$0.10 | $0.03 | Beat 128.74% | $9.8M |
| Apr 30, 2026 | -$0.20 | -$0.19 | Beat 5.00% | $1.4M |
| Mar 13, 2026 | -$0.21 | -$0.18 | Beat 14.62% | $223.7K |
| Nov 4, 2025 | -$0.22 | -$0.20 | Beat 9.09% | $1.2M |
| Apr 30, 2025 | -$0.22 | -$0.21 | Beat 4.55% | $1.2M |
| Mar 13, 2025 | -$0.21 | -$0.18 | Beat 14.29% | $1.3M |
| Mar 14, 2024 | -$0.07 | -$0.06 | Beat 14.29% | $17.3M |
| Nov 3, 2023 | -$0.02 | -$0.20 | Miss -754.34% | — |
| Aug 4, 2023 | -$0.22 | -$0.22 | In line | — |
| Apr 28, 2023 | -$0.24 | -$0.23 | Beat 4.17% | — |
| Mar 16, 2023 | -$0.28 | -$0.24 | Beat 14.29% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026